EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Theo Kofidis
Axel Haverich
Robert Clayton Robbins
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kofidis, T.
Right arrow Articles by Robbins, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kofidis, T.
Right arrow Articles by Robbins, R. C.
Related Collections
Right arrow Cardiac - other
Right arrow Myocardial infarction

Eur J Cardiothorac Surg 2005;28:461-466
© 2005 Elsevier Science NL


Original articles

They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response{star}

Theo Kofidis a , c , * , Jorg Lucas deBruin a , Masashi Tanaka a , Monika Zwierzchoniewska a , Irving Weissman b , Eugenia Fedoseyeva a , Axel Haverich c , Robert Clayton Robbins a

a Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, USA
b Department of Pathology and Developmental Biology, Stanford University Medical School, USA
c Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany

Received 25 October 2004; received in revised form 21 February 2005; accepted 9 March 2005.

* Corresponding author. Address: THG-Chirurgie, Medizinische Hochschule Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany. Tel.: +49 511 532 0; fax: +49 511 532 5404. (Email: kofidis{at}thg.mh-hannover.de; tkofidis{at}stanford.edu).

Abstract

Objective: The in vivo immunogenicity of Embryonic Stem Cells is controversial. At present, there is only in vitro evidence of MHC I expression by this cell population but vivid speculation about their immune-privileged state. The immunology aspect of ESC transplantation deserves thorough investigation. Methods: We injected mouse ESC (expressing Green Fluorescent Protein, GFP) into injured myocardium of syngeneic, allogeneic and SCID recipients. Furthermore, we monitored host response for up to 4 weeks post cell transfer. We determined local response (CD 3, CD 11c expression by host cells), MHC I expression by donor cells, MHC-II expression within and around the graft, humoral response of allogeneic hosts using Flow Cytometry and evaluated the hosts' cytokine response using stimulated spleenocytes by means of ELISPOT. Cell survival was estimated by morphometry, by calculating the area of the GFP+ graft over the area of infarction at multiple sections of the harvested heart. Results: There was significant cellular infiltration into and around the graft consisting of T-lymphocytes (CD3+) and dendritic cells (CD 11c). Infiltration was detectable at 1 week and progressed through 4 weeks following cell transplantation. The humoral Ab response was moderate at 2 weeks but frank at 4 weeks. ELISPOT demonstrated a Th1 pathway of donor specific T-lymphocyte response with strong IFN-{gamma} and Il-2 production (figure A). MHC I expression was significant within the graft and maximal in the allogeneic groups. Conclusions: An immune response against transplanted ESC was demonstrated and the future use of ESC will likely require the use of systemic immunosuppression.

Key Words: Stem cells • Myocardial repair • Ischemic cardiomyopathy




This article has been cited by other articles:


Home page
Stem CellsHome page
C. A. Koch, P. Geraldes, and J. L. Platt
Immunosuppression by Embryonic Stem Cells
Stem Cells, January 1, 2008; 26(1): 89 - 98.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
L. W. van Laake, R. Hassink, P. A. Doevendans, and C. Mummery
Heart repair and stem cells
J. Physiol., December 1, 2006; 577(2): 467 - 478.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
S. Bonde and N. Zavazava
Immunogenicity and Engraftment of Mouse Embryonic Stem Cells in Allogeneic Recipients
Stem Cells, October 1, 2006; 24(10): 2192 - 2201.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Anversa, J. Kajstura, A. Leri, and R. Bolli
Life and Death of Cardiac Stem Cells: A Paradigm Shift in Cardiac Biology
Circulation, March 21, 2006; 113(11): 1451 - 1463.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
T. Kofidis, D. R. Lebl, R.-J. Swijnenburg, J. M. Greeve, U. Klima, J. Gold, C. Xu, and R. C. Robbins
Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury
Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 50 - 55.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Eschenhagen and W. H. Zimmermann
Engineering Myocardial Tissue
Circ. Res., December 9, 2005; 97(12): 1220 - 1231.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.